Brief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
03/06/2026 16:26
BRIEF-Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan June 3 (Reuters) - Immunotech Biopharm Ltd 6978.HK:
IMMUNOTECH BIOPHARM - RECEIVES CONDITIONAL APPROVAL IN SEPT 2025 FOR CLINICAL TRANSLATIONAL APPLICATION OF ATL IN HAINAN
Further company coverage: 6978.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunotech Biopharm
See all newsBrief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
Brief: Trading In Shares Of Immunotech Biopharm Will Be Halted At 1:00 PM On April 28, HKEX Says
Brief: Immunotech Biopharm Posts Loss And Total Comprehensive Expense For Year Attributable Rmb230.8 Million
Brief: Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN